Bennett, AH, Godlee, RJ. Case of cerebral tumour. Medico-Chirurg Transact 68:243–75, 1885.Google ScholarPubMed

Walker, MD, Alexander, E, Jr., Hunt, WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–43, 1978.CrossRefGoogle ScholarPubMed

Cairncross, JG, Ueki, K, Zlatescu, MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–9, 1998.CrossRefGoogle ScholarPubMed

Naqvi, R, Garber, A. From trephining to genotyping: a brief look at the history of neuro-oncology. UWOMJ 76:19–21, 2007.Google Scholar

American Cancer Society. I: Cancer Facts and Figures 2005. Surveillance Research. Atlanta, GA: American Cancer Society; 2005, pp. 1–60.Google Scholar

Central Brain Tumor Registry of the United States (CBTRUS). Statistical Report: Primary Brain Tumors in the United States, 2004–2005. Chicago, IL: CBTRUS; 2004–2005.Google Scholar

Hess, KR, Broglio, KR, Bondy, ML. Adult glioma incidence trends in the United States, 1977–2000. Cancer 101:2293–9, 2004.CrossRefGoogle ScholarPubMed

Chamberlain, MC, Kormanik, PA. Practical guidelines for the treatment of malignant gliomas. West J Med 168:114–20, 1998.Google ScholarPubMed

Stupp, R, Mason, WP, van den Bent, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–96, 2005.CrossRefGoogle ScholarPubMed

Chinot, OL, Wick, W, Mason, W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–22, 2014.CrossRefGoogle ScholarPubMed

Gilbert, MR, Dignam, JJ, Armstrong, TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708, 2014.CrossRefGoogle ScholarPubMed

McLendon, R, Rosenblum, M, Bigner, D. Russell and Rubinstein’s Pathology of Tumors of the Nervous System (7th ed.). London: Hodder Arnold, 2006.CrossRefGoogle Scholar

Stupp, R, Mason, WP, van den Bent, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–96, 2005.CrossRefGoogle ScholarPubMed

Chinot, OL, Wick, W, Mason, W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–22, 2014.CrossRefGoogle ScholarPubMed

Friedman, HS, Prados, MD, Wen, PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–40, 2009.CrossRefGoogle ScholarPubMed

Wick, W, Puduvalli, VK, Chamberlain, MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–74, 2010.CrossRefGoogle ScholarPubMed

Batchelor, TT, Mulholland, P, Neyns, B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–18, 2013.CrossRefGoogle ScholarPubMed

Stupp, R, Hegi, ME, Mason, WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–66, 2009.CrossRefGoogle Scholar

Zalutsky, MR, Moseley, RP, Coakham, HB, et al. Pharmacokinetics and tumor localization of ¹³¹I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49:2807–13, 1989.Google ScholarPubMed

Groothuis, DR, Fischer, JM, Lapin, G, et al. Permeability of different experimental brain tumor models to horseradish peroxidase. J Neuropathol Exp Neurol 41:164–85, 1982.CrossRefGoogle ScholarPubMed

Neuwelt, EA, Barnett, PA, Bigner, DD, et al. Effects of adrenal cortical steroids and osmotic blood–brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood–brain barrier. Proc Natl Acad Sci U S A 79:4420–3, 1982.CrossRefGoogle ScholarPubMed

Fenstermacher, JD, Rall, DP, Patlak, CS. Ventriculocisternal perfusion as a technique for analysis of brain capillary permeability and extracellular transport. Capillary permeability. Presented at the Alfred Benzon Symposium, 1969.Google Scholar

Bigner, DD, Bigner, SH, Ponten, J, et al. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 40:201–29, 1981.CrossRefGoogle ScholarPubMed

Chin, L, Meyerson, M, Aldape, K, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–8, 2008.Google Scholar

Parsons, DW, Jones, S, Zhang, XS, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–12, 2008.CrossRefGoogle ScholarPubMed

Yan, H, Parsons, DW, Jin, GL, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–73, 2009.CrossRefGoogle ScholarPubMed

Gumerlock, MK, Neuwelt, EA. Principles of chemotherapy in brain neoplasia. In Jellinger, K (ed.) Therapy of Malignant Brain Tumors. New York, NY: Springer-Verlag, 1987.Google Scholar

Gehan, EA, Walker, MD. Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr 46:189–95, 1977.Google ScholarPubMed

Chin, HW, Young, AB, Maruyama, Y. Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center. Cancer Treat Rep 65:45–51, 1981.Google ScholarPubMed

Walker, MD, Green, SB, Byar, DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–9, 1980.CrossRefGoogle ScholarPubMed

Gaspar, LE, Fisher, BJ, Macdonald, DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55–7, 1992.CrossRefGoogle ScholarPubMed

Hochberg, FH, Pruitt, A. Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–11, 1980.CrossRefGoogle ScholarPubMed

Brem, H, Tamargo, RJ, Olivi, A, et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80:283–90, 1994.CrossRefGoogle ScholarPubMed

Brem, H, Piantadosi, S, Burger, PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–12, 1995.CrossRefGoogle ScholarPubMed

Westphal, M, Hilt, DC, Bortey, E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88, 2003.CrossRefGoogle ScholarPubMed

Yung, A, Levin, V, Albright, R, et al. Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. In Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA: American Society of Clinical Oncology; 1999.Google Scholar

Yung, WK, Jaeckle, K, Kyritsis, A, et al. A combination of temozolomide and interferon-A in recurrent malignant gliomas. A phase II study. In Fourth Annual Meeting of the Society for Neuro-Oncology. Scottsdale, AZ, Carden Jennings; 1999.Google Scholar

Friedman, HS, Kokkinakis, DM, Pluda, J, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16:3570–5, 1998.CrossRefGoogle ScholarPubMed

Gerson, SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296–307, 2004.CrossRefGoogle ScholarPubMed

Hegi, ME, Diserens, AC, Gorlia, T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003, 2005.CrossRefGoogle ScholarPubMed

Tolcher, AW, Gerson, SL, Denis, L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–11, 2003.CrossRefGoogle ScholarPubMed

Bertolini, F, Paul, S, Mancuso, P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342–6, 2003.Google ScholarPubMed

Kerbel, RS, Kamen, BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–36, 2004.CrossRefGoogle ScholarPubMed

Perry, JR, Belanger, K, Mason, WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051–7, 2010.CrossRefGoogle ScholarPubMed

Gilbert, MR, Wang, M, Aldape, KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085–91, 2013.CrossRefGoogle ScholarPubMed

Kleihues, P, Cavenee, WK. Pathology and Genetics Tumours of the Nervous System. Lyons: IARC Press; 2000.Google Scholar

Chaudhry, IH, O’Donovan, DG, Brenchley, PE, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39:409–15, 2001.CrossRefGoogle ScholarPubMed

Ke, LD, Shi, YX, Im, SA, et al. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res 6:2562–72, 2000.Google ScholarPubMed

Plate, KH, Breier, G, Weich, HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–8, 1992.CrossRefGoogle ScholarPubMed

Samoto, K, Ikezaki, K, Ono, M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55:1189–93, 1995.Google ScholarPubMed

Longo, R, Sarmiento, R, Fanelli, M, et al. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5:237–56, 2002.CrossRefGoogle ScholarPubMed

Kim, KJ, Li, B, Winer, J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–4, 1993.CrossRefGoogle ScholarPubMed

Presta, LG, Chen, H, O’Connor, SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–9, 1997.Google ScholarPubMed

Ferrara, N, Hillan, KJ, Gerber, HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400, 2004.Google ScholarPubMed

Hurwitz, H, Fehrenbacher, L, Novotny, W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–42, 2004.CrossRefGoogle ScholarPubMed

Sandler, A, Gray, R, Perry, MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–50, 2006.CrossRefGoogle ScholarPubMed

Miller, K, Wang, M, Gralow, J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–76, 2007.CrossRefGoogle ScholarPubMed

Stark-Vance, V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. In Abstracts from the World Federation of Neuro-Oncology Meeting, 2005, p. 91.Google Scholar

Vredenburgh, JJ, Desjardins, A, Herndon, JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–9, 2007.CrossRefGoogle ScholarPubMed

Vredenburgh, JJ, Desjardins, A, Herndon, JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–9, 2007.CrossRefGoogle ScholarPubMed

Desjardins, A, Reardon, DA, Herndon, JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14:7068–73, 2008.CrossRefGoogle ScholarPubMed

Cloughesy, T, Vredenburgh, JJ, Day, B, et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol 28:15s, 2010.CrossRefGoogle Scholar

Kreisl, TN, Kim, L, Moore, K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–5, 2009.CrossRefGoogle ScholarPubMed

Geng, L, Donnelly, E, McMahon, G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413–19, 2001.Google ScholarPubMed

Kozin, SV, Boucher, Y, Hicklin, DJ, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61:39–44, 2001.Google ScholarPubMed

Chinot, OL, Wick, W, Mason, W, et al. Bevacizumab plus radiotherapy – temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–22, 2014.CrossRefGoogle ScholarPubMed

Wen, PY, Macdonald, DR, Reardon, DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–72, 2010.CrossRefGoogle ScholarPubMed

Brandes, AA, Franceschi, E, Tosoni, A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–7, 2008.CrossRefGoogle ScholarPubMed

Fine, HA. Bevacizumab in glioblastoma – still much to learn. N Engl J Med 370:764–5, 2014.CrossRefGoogle ScholarPubMed

Reardon, DA, Herndon, JE, 2nd, Peters, KB, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer 107:1481–7, 2012.CrossRefGoogle ScholarPubMed

Taal, W, Oosterkamp, HM, Walenkamp, AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–53, 2014.CrossRefGoogle ScholarPubMed

Dirven, L, van den Bent, MJ, Bottomley, A, et al. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer 51(10):1321–30, 2015.CrossRefGoogle ScholarPubMed